Sanofi-aventis has reported the results of a phase II study with teriflunomide, a novel orally available immunomodulatory therapy for multiple sclerosis (MS). Teriflunomide is currently being explored in
Germany-based Merck has reported the results of the complete 40-week IMPROVE (Investigating MRI Parameters with Rebif imprOVEd formulation) study. Reportedly, the data showed a 69% reduction in the
Germany-based Merck has reported new data from a post-hoc analysis of the two-year (96-week) placebo-controlled CLARITY phase III trial, using a short-course of Cladribine Tablets. Cladribine Tablets (the
American Oriental Bioengineering (AOBO) has launched a new over-the-counter (OTC) product – YuYeQingHuo Capsules (YYQH). YYQH will be manufactured by the company’s Boke subsidiary. It will be marketed
The FDA has approved GenSpera’s Investigational New Drug (IND) application to begin a phase I study with its target activated pro-drug, G-202, for the treatment of cancer. G-202
Levi & Korsinsky, a law firm has filed lawsuit in Delaware Chancery court challenging the proposed acquisition of Sepracor. The complaint arises out of the announcement by Sepracor
Access Pharmaceuticals (Access) has entered into an agreement with a commercial manufacturer, Accupac, to produce its FDA-approved MuGard for North American distribution. MuGard is a novel, ready-to-use mucoadhesive
The FDA has cleared a test that can help detect ovarian cancer in a pelvic mass that is already known to require surgery. The test, known as OVA1,
Delcath Systems has reported that the Data and Safety Monitoring Board (DSMB) has reviewed clinical data on 77 patients enrolled in its pivotal phase III clinical trial. DSMB
AgraQuest and Alpharma Animal Health have agreed to terms for a supply agreement in which AgraQuest will supply their strain of Bacillus subtilis. This input will be used
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.